The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Hemolytic-Uremic Syndrome

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Hemolytic-Uremic Syndrome


High impact information on Hemolytic-Uremic Syndrome


Chemical compound and disease context of Hemolytic-Uremic Syndrome


Biological context of Hemolytic-Uremic Syndrome


Anatomical context of Hemolytic-Uremic Syndrome


Gene context of Hemolytic-Uremic Syndrome


Analytical, diagnostic and therapeutic context of Hemolytic-Uremic Syndrome


  1. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. Sarkodee-Adoo, C., Gojo, I., Heyman, M.R. N. Engl. J. Med. (1999) [Pubmed]
  2. Role of plasminogen-activator inhibitor type 1 in the pathogenesis and outcome of the hemolytic uremic syndrome. Bergstein, J.M., Riley, M., Bang, N.U. N. Engl. J. Med. (1992) [Pubmed]
  3. von Willebrand factor cleaving protease and ADAMTS13 mutations in childhood TTP. Schneppenheim, R., Budde, U., Oyen, F., Angerhaus, D., Aumann, V., Drewke, E., Hassenpflug, W., Häberle, J., Kentouche, K., Kohne, E., Kurnik, K., Mueller-Wiefel, D., Obser, T., Santer, R., Sykora, K.W. Blood (2003) [Pubmed]
  4. Increased fragmentation of von Willebrand factor, due to abnormal cleavage of the subunit, parallels disease activity in recurrent hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and discloses predisposition in families. The Italian Registry of Familial and Recurrent HUS/TTP. Galbusera, M., Noris, M., Rossi, C., Orisio, S., Caprioli, J., Ruggeri, Z.M., Amadei, B., Ruggenenti, P., Vasile, B., Casari, G., Remuzzi, G. Blood (1999) [Pubmed]
  5. Detection of serum antibodies to the lipopolysaccharide of Escherichia coli O103 in patients with hemolytic-uremic syndrome. Luzzi, I., Tozzi, A.E., Rizzoni, G., Niccolini, A., Benedetti, I., Minelli, F., Caprioli, A. J. Infect. Dis. (1995) [Pubmed]
  6. Prothrombotic coagulation abnormalities preceding the hemolytic-uremic syndrome. Chandler, W.L., Jelacic, S., Boster, D.R., Ciol, M.A., Williams, G.D., Watkins, S.L., Igarashi, T., Tarr, P.I. N. Engl. J. Med. (2002) [Pubmed]
  7. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. Warwicker, P., Goodship, J.A., Goodship, T.H. N. Engl. J. Med. (1999) [Pubmed]
  8. Letter: Heparin for the hemolytic uremic syndrome. Kaplan, B.S., Thompson, P.D. N. Engl. J. Med. (1976) [Pubmed]
  9. Gemcitabine-induced hemolytic uremic syndrome: a case report. Brodowicz, T., Breiteneder, S., Wiltschke, C., Zielinski, C.C. J. Natl. Cancer Inst. (1997) [Pubmed]
  10. A reporter transgene indicates renal-specific induction of tumor necrosis factor (TNF) by shiga-like toxin. Possible involvement of TNF in hemolytic uremic syndrome. Harel, Y., Silva, M., Giroir, B., Weinberg, A., Cleary, T.B., Beutler, B. J. Clin. Invest. (1993) [Pubmed]
  11. Hemolytic uremic syndrome in a patient treated with clopidogrel. Oomen, P.H., Tulleken, J.E., Zijlstra, J.G. Ann. Intern. Med. (2000) [Pubmed]
  12. The treatment of the hemolytic-uremic syndrome with inhibitors of platelet function. Thorsen, C.A., Rossi, E.C., Green, D., Carone, F.A. Am. J. Med. (1979) [Pubmed]
  13. Late acute failure of well-HLA-matched renal allografts with capillary congestion and arteriolar thrombi. Hourmant, M., Buzelin, F., Dantal, J., van Dixhoorn, M., Le Forestier, M., Coste, M., Cantarovich, D., Moreau, A., Bignon, J.D., van der Woude, F. Transplantation (1995) [Pubmed]
  14. The role of lipopolysaccharide and Shiga-like toxin in a mouse model of Escherichia coli O157:H7 infection. Karpman, D., Connell, H., Svensson, M., Scheutz, F., Alm, P., Svanborg, C. J. Infect. Dis. (1997) [Pubmed]
  15. Enhanced endothelial cell apoptosis in splenic tissues of patients with thrombotic thrombocytopenic purpura. Dang, C.T., Magid, M.S., Weksler, B., Chadburn, A., Laurence, J. Blood (1999) [Pubmed]
  16. Hypocomplementemia discloses genetic predisposition to hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: role of factor H abnormalities. Italian Registry of Familial and Recurrent Hemolytic Uremic Syndrome/Thrombotic Thrombocytopenic Purpura. Noris, M., Ruggenenti, P., Perna, A., Orisio, S., Caprioli, J., Skerka, C., Vasile, B., Zipfel, P.F., Remuzzi, G. J. Am. Soc. Nephrol. (1999) [Pubmed]
  17. ABO and P1 blood group antigen expression and stx genotype and outcome of childhood Escherichia coli O157:H7 infections. Jelacic, S., Wobbe, C.L., Boster, D.R., Ciol, M.A., Watkins, S.L., Tarr, P.I., Stapleton, A.E. J. Infect. Dis. (2002) [Pubmed]
  18. Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome. Manuelian, T., Hellwage, J., Meri, S., Caprioli, J., Noris, M., Heinen, S., Jozsi, M., Neumann, H.P., Remuzzi, G., Zipfel, P.F. J. Clin. Invest. (2003) [Pubmed]
  19. The successful use of tacrolimus (FK506) in a pancreas/kidney transplant recipient with recurrent cyclosporine-associated hemolytic uremic syndrome. Kaufman, D.B., Kaplan, B., Kanwar, Y.S., Abecassis, M., Stuart, F.P. Transplantation (1995) [Pubmed]
  20. Shiga toxin-associated hemolytic uremic syndrome: combined cytotoxic effects of shiga toxin and lipopolysaccharide (endotoxin) on human vascular endothelial cells in vitro. Louise, C.B., Obrig, T.G. Infect. Immun. (1992) [Pubmed]
  21. A DNA probe to identify enterohemorrhagic Escherichia coli of O157:H7 and other serotypes that cause hemorrhagic colitis and hemolytic uremic syndrome. Levine, M.M., Xu, J.G., Kaper, J.B., Lior, H., Prado, V., Tall, B., Nataro, J., Karch, H., Wachsmuth, K. J. Infect. Dis. (1987) [Pubmed]
  22. Development of insulin-dependent diabetes mellitus during the hemolytic-uremic syndrome. Andreoli, S.P., Bergstein, J.M. J. Pediatr. (1982) [Pubmed]
  23. Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome. Richards, A., Kemp, E.J., Liszewski, M.K., Goodship, J.A., Lampe, A.K., Decorte, R., Müslümanoğlu, M.H., Kavukcu, S., Filler, G., Pirson, Y., Wen, L.S., Atkinson, J.P., Goodship, T.H. Proc. Natl. Acad. Sci. U.S.A. (2003) [Pubmed]
  24. Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura. Bianchi, V., Robles, R., Alberio, L., Furlan, M., Lämmle, B. Blood (2002) [Pubmed]
  25. Administration of ricin induces a severe inflammatory response via nonredundant stimulation of ERK, JNK, and P38 MAPK and provides a mouse model of hemolytic uremic syndrome. Korcheva, V., Wong, J., Corless, C., Iordanov, M., Magun, B. Am. J. Pathol. (2005) [Pubmed]
  26. Interleukin-8 and polymorphoneutrophil leucocyte activation in hemolytic uremic syndrome of childhood. Fitzpatrick, M.M., Shah, V., Trompeter, R.S., Dillon, M.J., Barratt, T.M. Kidney Int. (1992) [Pubmed]
  27. Factor H mutations in hemolytic uremic syndrome cluster in exons 18-20, a domain important for host cell recognition. Richards, A., Buddles, M.R., Donne, R.L., Kaplan, B.S., Kirk, E., Venning, M.C., Tielemans, C.L., Goodship, J.A., Goodship, T.H. Am. J. Hum. Genet. (2001) [Pubmed]
  28. Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases. Veyradier, A., Obert, B., Houllier, A., Meyer, D., Girma, J.P. Blood (2001) [Pubmed]
  29. Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies. Kreitman, R.J., Squires, D.R., Stetler-Stevenson, M., Noel, P., FitzGerald, D.J., Wilson, W.H., Pastan, I. J. Clin. Oncol. (2005) [Pubmed]
  30. De novo hemolytic uremic syndrome after kidney transplantation in patients treated with cyclosporine-sirolimus combination. Langer, R.M., Van Buren, C.T., Katz, S.M., Kahan, B.D. Transplantation (2002) [Pubmed]
  31. Evidence for a hybrid genomic island in verocytotoxin-producing Escherichia coli CL3 (serotype O113:H21) containing segments of EDL933 (serotype O157:H7) O islands 122 and 48. Shen, S., Mascarenhas, M., Rahn, K., Kaper, J.B., Karmali, M.A., Karmal, M.A. Infect. Immun. (2004) [Pubmed]
  32. Escherichia coli O157 fails to induce a long-lasting lipopolysaccharide-specific, measurable humoral immune response in children with hemolytic-uremic syndrome. Ludwig, K., Bitzan, M., Bobrowski, C., Müller-Wiefel, D.E. J. Infect. Dis. (2002) [Pubmed]
WikiGenes - Universities